The principal close level was the security and tolerability of sifalimumab. Remedy-emergent adverse activities (AEs) and major AEs (SAEs) and their severity, result, and any partnership on the analyze medication have been recorded via the investigator through the research. AEs were regarded more likely to be relevant to study medication https://johnt000jwg4.wikimeglio.com/user